Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug495 | BNT162c2 Wiki | 1.00 |
| drug491 | BNT162a1 Wiki | 1.00 |
| drug493 | BNT162b2 Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012327 | RNA Virus Infections NIH | 0.41 |
| D012141 | Respiratory Tract Infections NIH | 0.16 |
| D014777 | Virus Diseases NIH | 0.11 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).
Description: Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], molecular CR [CRm], or CRh per Interworking Group AML response criteria.
Measure: Efficacy based on CR/CRh rate Time: 14 monthsDescription: Rate of CR + CRh + CRi (CR with incomplete blood cell recovery [CR with incomplete neutrophil or platelet recovery]) + MLFS (morphologic leukemia-free state)
Measure: Overall complete response rate Time: 14 monthsDescription: Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], or molecular CR [CRm] per Interworking Group AML response criteria.
Measure: CR rate Time: 14 monthsDescription: Proportion of patients achieving a best response of CRh per Interworking Group AML response criteria.
Measure: CRh rate Time: 14 monthsDescription: Time of initial documentation of response to the time of disease relapse, progression, or death due to any cause, whichever occurs first.
Measure: Duration of response Time: Up to 2 yearsDescription: The rate of conversion from transfusion dependence to transfusion independence will be calculated. The rate of patients who are transfusion independent at baseline and remain independent during any 56-day post-baseline period will also be calculated.
Measure: Transfusion independence rate Time: 56 daysDescription: Time from first dose to death from any cause
Measure: Overall survival Time: Up to 2 yearsDescription: Rate of successful hematopoietic stem cell transplantation (HSCT) through flotetuzumab treatment but before subsequent therapy.
Measure: HSCT rate Time: 8 monthsDescription: Incidence rate of hospitalization will be calculated
Measure: Incidence rate of hospitalization Time: 8 monthsDescription: Duration of hospitalization will be characterized
Measure: Duration of hospitalization Time: 8 monthsDescription: Time from the first dose of study drug until date of evidence of progression, relapse, or death from any cause, whichever occurs first.
Measure: Event-free survival Time: Up to 2 yearsDescription: Time from first dose of study drug to first CR, CRh, CR with incomplete blood cell recovery (CRi), CR with incomplete neutrophil recovery (CRn), CR with incomplete platelet recover (CRp), or morphologic leukemia-free state (MLFS)
Measure: Time to response Time: 14 monthsDescription: rate of death from any cause within 30, 60, 90, or 180 days of first dose of study drug
Measure: Mortality rate Time: Up to 180 daysDescription: Probability of survival at 6 months from first dose of study drug
Measure: 6-month survival rate Time: 6 monthsDescription: Probability of survival at 1 year from first dose of study drug
Measure: One-year survival rate Time: 1 yearDescription: Maximum Tolerated Dose/Schedule: the MTDS is defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is < 33% during the first cycle of MGD006 treatment.
Measure: Occurrence of dose limiting toxicity Time: Cycle 1 of a 28 day cycle.Description: Cycle 1 through end of treatment
Measure: Occurrence of adverse events (AEs) and serious adverse events (SAEs) Time: 9 monthsDescription: Measure the pharmacokinetics (PK) of flotetuzumab
Measure: Serum concentration of flotetuzumab Time: Cycles 1 and 2 (28-day cycles) and 28 days after the last doseDescription: Occurrence of anti-drug antibody
Measure: ADA Time: Day 1 of Cycle 1 and Day 1 of Cycle 2 (28-day cycles)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports